Kras as a key oncogene and therapeutic target in pancreatic cancer - Wikidata - wikimedia - TriplyDB

Kras as a key oncogene and therapeutic target in pancreatic cancer

Kras as a key oncogene and therapeutic target in pancreatic cancer

http://www.wikidata.org/entity/Q34659332

about

Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer Noncoding RNAs and pancreatic cancer Novel agents for advanced pancreatic cancer Pancreatic cancer, treatment options, and GI-4000 Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling Soluble factors from stellate cells induce pancreatic cancer cell proliferation via Nrf2-activated metabolic reprogramming and ROS detoxification Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines.Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer Pancreatic cancer, treatment options, and GI-4000.A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells.Selective killing of K-ras-transformed pancreatic cancer cells by targeting NAD(P)H oxidase.Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.Molecular Imaging with MRI: Potential Application in Pancreatic Cancer.The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma.Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3 Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus.The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.miR-217 regulates tumor growth and apoptosis by targeting the MAPK signaling pathway in colorectal cancer.Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.Stiehopus japonieus acidic mucopolysaccharide inhibits the proliferation of pancreatic cancer SW1990 cells through Hippo-YAP pathway.Genetic modification of hypoxia signaling in animal models and its effect on cancer.MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.Direct Modulation of Small GTPase Activity and Function.Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges.Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.

P2860

Q26764921-2AC1AB58-9258-42F1-A772-07C94051C8E8 Q26774630-4EAE61CD-3BA8-4F71-9152-142D899CABB6 Q26787087-76AE6DD3-5E91-42BC-BED5-7BD1ACA1724A Q28083814-04E5D7B4-C21D-49DB-A70B-26C0BD4595C1 Q28547017-A87299D1-3FAA-4AF3-862C-9794CB8B0BC4 Q28552433-4EA38F55-2661-4517-917D-93544ADB67B8 Q28822225-33F51C62-E043-419F-83A5-4BCEAA2211E8 Q31060752-6CC2E29B-9C6D-4BD8-AB6B-600B62A88EB7 Q33624574-782EA80E-B589-428C-9A38-04AE3093702A Q33838679-1EE8A8FD-1DA8-43E2-A074-525E62EA8A60 Q34104152-0C2AE7DE-937B-4B8D-B608-71C3AE013CEF Q34405468-8C1EDF57-9629-4B65-A135-907510AF6AAC Q34690409-B1B092C7-4813-4211-A15B-08DF8748104A Q35136815-66990E92-7CA5-4DB0-B3D9-1AA6D180AD22 Q35597456-EA47B076-BA29-4F51-A304-2E6BC60FE768 Q35612378-C5EA3599-C3A3-46C4-89FE-3F2FCD7EBE9C Q35887099-134D2DE2-712B-4469-9AB7-36192F705B58 Q35981873-612E4454-F292-4FB8-8DBE-77F53FA2AF66 Q36016816-F7F53429-2063-42A2-BD2C-C1B2E5478036 Q36121107-9DE47F40-5250-4B00-A055-50FD0A8B9985 Q36180749-456BCEA8-4DD6-4967-AD44-8C20B0594DB9 Q36249508-65FE8360-538A-44F6-800F-97A4D6F3DA75 Q36540519-5AA9E06A-EC0C-4AAF-8840-4BD07B64F90A Q36546544-EA2FEB24-8C57-444C-8D68-8D26FD20F026 Q36562030-E1ED8FC7-38B3-4190-B983-BD74FD5C65CB Q36629420-9A1C65D1-2791-4BD1-B10F-819AA324AFD2 Q36782324-17911929-057E-4077-B2D0-0A38580DA61F Q37123636-33A274B1-320E-465B-BDC8-3A1938BCD488 Q37238133-8E0B5C2D-44F1-45E9-B3A3-371C02206E3D Q37271741-9DB09051-CF8F-4484-BAE0-325B063F7C42 Q37569554-E1FB48DE-F7DB-4DD8-B131-D8E39B0CA8D6 Q37582210-FE74F4D0-3781-4F96-9E68-62233CBDA906 Q37702589-C6A75038-9F56-418C-89EF-3B0C6F3BD3BD Q37725431-06FBD814-B272-444E-AECA-7234BB0BF93B Q38263349-F75DFFA6-ED17-4689-9FB2-0AB3940361BD Q38471156-562566DC-30D5-47F9-92A1-517C83381AC7 Q38591066-7429D064-0CE5-497B-80D2-ECF7E5014831 Q38608107-E1FC2424-9205-4DEF-9465-7DD82ABCC7FC Q38680160-73A7A89E-FA89-4271-A594-D9DA9F0A6CC0 Q38714341-9ED4DDCA-0637-437E-857A-6DD401B84EA5

P2860

Kras as a key oncogene and therapeutic target in pancreatic cancer

http://www.wikidata.org/entity/Q34659332

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Kras as a key oncogene and therapeutic target in pancreatic cancer

@ast

Kras as a key oncogene and therapeutic target in pancreatic cancer

@en

Kras as a key oncogene and therapeutic target in pancreatic cancer

@nl

type

label

Kras as a key oncogene and therapeutic target in pancreatic cancer

@ast

Kras as a key oncogene and therapeutic target in pancreatic cancer

@en

Kras as a key oncogene and therapeutic target in pancreatic cancer

@nl

prefLabel

Kras as a key oncogene and therapeutic target in pancreatic cancer

@ast

Kras as a key oncogene and therapeutic target in pancreatic cancer

@en

Kras as a key oncogene and therapeutic target in pancreatic cancer

@nl

P1433

Q34659332-01A78C2A-E853-4DA0-884D-2DD0991EA9C7

P1476

Q34659332-34DD5164-2C88-47A7-8D46-586CA81BC4B1

P2093

Q34659332-38E86553-7B1E-4A5F-8613-CB5367236A33

Q34659332-815DA643-19A3-4D0D-BF48-69D8905A1250

P2860

Q34659332-002656D9-6CB6-450A-87AB-BF80B3CD823A

Q34659332-028BB7E2-32B5-4371-BF2C-F99E42C2BA13

Q34659332-07A5E06F-B020-4A2C-A505-10010732F41B

Q34659332-0B14A8EB-406E-451B-9DB8-5C527EB23A59

Q34659332-0E099734-3118-4271-AE5A-019ACC837670

Q34659332-10131F06-2762-4266-955E-07E753F43363

Q34659332-123640BA-654B-4C2B-97EA-1FA2486E51DE

Q34659332-15143D4D-1F78-4198-A9BA-9972FF7797D4

Q34659332-1946503F-DA64-4473-A350-8BDA00ECE8A6

Q34659332-1A58EB15-3E04-4C0E-8DB0-B011C95B60B8

P304

Q34659332-818EACD7-6E96-4B5D-ACD2-A9B5458C5F07

P31

Q34659332-FAFEE53D-E15A-4ABD-B997-B8B42B127F25

P356

Q34659332-06368FDC-1C82-4501-A997-DD1F68907149

P478

Q34659332-B0898EE9-AC5C-48F4-9F7D-3ADDB4BB822C

P577

Q34659332-737F964F-6B86-483D-8A68-E2174D20CB43

P5875

Q34659332-7D4BBFB2-AEB0-4C6B-B75A-EEE402221034

P698

Q34659332-ACED63BF-B2AF-4893-BFEC-3B0C2695D886

P932

Q34659332-3858CE9C-5884-47CD-9304-6A1EDE3A8E36

P356

FPHYS.2013.00407

P1433

Frontiers in Physiology

P1476

Kras as a key oncogene and therapeutic target in pancreatic cancer

@en

P2093

Marina Pasca di Magliano

http://www.w3.org/2001/XMLSchema#string

Meredith A Collins

http://www.w3.org/2001/XMLSchema#string

P2860

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

Inflammatory networks and immune surveillance of pancreatic carcinoma

Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

P304

407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHYS.2013.00407

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259986467

http://www.w3.org/2001/XMLSchema#string

P698

24478710

http://www.w3.org/2001/XMLSchema#string

P932

3896882

http://www.w3.org/2001/XMLSchema#string